Should I Buy CRDF? CRDF 2026 Analysis

Should You Buy Cardiff Oncology Inc (CRDF) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

1.600

1 Day change

8.11%

52 Week Range

4.990

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy (speculative) at current levels (~$1.67) because the stock is deeply oversold near key support and options positioning is strongly call-skewed, while Wall Street remains decisively bullish with large upside-to-target.
This is not a trend-following buy (trend is still bearish); it’s a mean-reversion/spec biotech entry where you’re paying a depressed price ahead of the next meaningful clinical update window (H1 2026).
If price fails to hold the ~$1.68 support zone, downside can accelerate toward the next support (~$1.33), so the buy thesis is strongest only while holding/recapturing that area.

Technical Analysis

Trend/MAs: Bearish structure (SMA_200 > SMA_20 > SMA_5) = primary trend still down.
Momentum (MACD): MACD histogram -0.136 (below zero) but negatively contracting → bearish momentum is easing, consistent with a potential basing attempt.
RSI (6): ~20.3, which is oversold (despite the provided label), often associated with short-term rebound potential.
Key levels: Price ~$1.67 is sitting on S1 ~1.678 (critical). If it holds and bounces, upside mean-reversion targets are pivot ~2.239 then R1 ~2.80; if it breaks, next downside reference is S2 ~1.331.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Very low put/call ratios (OI 0.19, volume 0.08) = bullish / call-heavy sentiment.
Volatility: 30D IV ~123% vs historical vol ~54% → options are pricing large moves, typical for small-cap biotech around clinical/regulatory uncertainty.
Activity: Today’s option volume (~199 contracts) is below recent averages (vs 5D/10D averages), suggesting no major near-term options crowding, but open interest is meaningfully call-skewed.

Technical Summary

Sell

Buy

Positive Catalysts

- Clinical catalyst setup: H.C. Wainwright cites updated CRDF-004 results as “highly encouraging” and expects a more mature dataset in H1 2026.
- Street support: Recent Buy/Outperform initiations/affirmations with $10–$12 targets can help stabilize sentiment after selloffs.
- Technical mean-reversion potential: Oversold RSI at a major support zone increases odds of a tradable bounce if support holds.

Neutral/Negative Catalysts

- Downtrend intact: Moving averages and MACD remain bearish; rebounds can fail quickly in a declining trend.
- Event risk / biotech binary risk: Future trial readouts can reprice the stock sharply in either direction.
- Weak operating profile: Minimal revenue base and ongoing losses increase financing/dilution risk.
- No near-term news flow: “No news in recent week” reduces immediate catalyst support; price may chop or drift until the next update cycle.

Financial Performance

Latest quarter: 2025/Q3
Revenue: $120K, down -27.27% YoY (very small base).
Net income: -$11.264M, worsened -5.03% YoY.
EPS: -0.17, down -32% YoY.
Takeaway: Financials reflect a clinical-stage company with continued cash burn; the equity story is driven primarily by trial progress, not near-term fundamentals.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Trend in ratings/targets: Recently constructive/bullish coverage with high targets despite volatility.
2026-01-28 (H.C. Wainwright): Reiterated Buy, $10 PT; called the prior selloff an “attractive entry point” on encouraging CRDF-004 updates; expects a more mature dataset in H1 2026.
2026-01-05 (Noble Capital): Initiated Outperform, $12 PT, highlighting onvansertib opportunity in metastatic colorectal cancer.
Wall Street pros: Strong upside targets, supportive interpretation of trial updates.
Wall Street cons: Targets are highly dependent on clinical success; until clearer clinical validation arrives, the stock can remain volatile and trend-driven.

6 Analyst Rating

Wall Street analysts forecast CRDF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDF is 13.67 USD with a low forecast of 10 USD and a high forecast of 19 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.480

Low

Averages

13.67

High

Current: 1.480

Low

Averages

13.67

High

H.C. Wainwright

Buy

maintain

$10

AI Analysis

2026-01-28

Reason

H.C. Wainwright

Price Target

$10

AI Analysis

2026-01-28

maintain

Buy

Reason

H.C. Wainwright says the selloff yesterday in shares of Cardiff Oncology brings an attractive entry point. The firm finds updated CRDF-004 trial results "highly encouraging." It expects a more mature clinical dataset from the CRDF-004 study in the first half of 2026. The market "overreaction provides an attractive entry point," says H.C. Wainwright. The analyst keeps a Buy rating on Cardiff Oncology with a $10 price target.

Noble Capital

initiated

$12

2026-01-05

Reason

Noble Capital

Price Target

$12

2026-01-05

initiated

Reason

Noble Capital initiated coverage of Cardiff Oncology with an Outperform rating and $12 price target. Cardiff is developing onvansertib for the treatment of multiple cancer indications, with the lead program in metastatic colorectal cancer for patients with a mutation that makes the cancer more aggressive and difficult to treat, the analyst noted. The firm values shares based on estimated FY30 EPS of $2.30 per share, discounted at 30% per year to allow for clinical and regulatory risks, the analyst says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRDF

Unlock Now

CRDF Should I Buy

CRDF Should I Buy

Should You Buy Cardiff Oncology Inc (CRDF) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch